ClinicalTrials.gg

Dyslipidemias clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,249 studies for Dyslipidemias across more than 10 countries. 177 are recruiting or about to start. 478 of them are mainly about Dyslipidemias (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 8 narrower conditions too, such as Hypercholesterolemia: 3,421 studies, 428 open.

ClinicalTrials.gov finds 3,535 studies for Dyslipidemias. How that becomes 1,249 here

This page counts the studies the registry files under Dyslipidemias, and those it files under no condition that list Dyslipidemiasthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 17, 2026. How condition pages count

  1. 3,535Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −2,101Filed under a narrower condition, counted on its own pageHypercholesterolemia 993 · Hyperlipidemias 651 · Hypertriglyceridemia 231 · Hyperlipoproteinemia Type II 152 · Homozygous Familial Hypercholesterolemia 37 · Hyperlipoproteinemias 15 · 2 more
  3. −14List Dyslipidemias as a condition, but the registry did not file them under itMost often written as “Atherogenic Dyslipidemia” (5), “Dyslipidemia Associated With Type II Diabetes Mellitus” (4), and “Diabetic Dyslipidemia” (1). The registry filed them under other conditions only, most often Diabetes Mellitus, Type 2 (6) and Insulin Resistance (5).
  4. −171Match it another way49 name it in the title, 6 in a keyword, and 116 by a synonym or other text the search reads.
  5. 1,249The count on this page47 of them list Dyslipidemias in their own words; the registry filed them under no condition.

Status

Completed
818
Status unknown
118
Recruiting
112
Terminated
56
Not yet recruiting
53
Active, not recruiting
47

Phase

Phase 3
218
Phase 1
153
Phase 2
148
Phase 4
133
Early Phase 1
5

Where

United States
349
Korea, Republic of
155
Canada
84
China
73
Netherlands
60
Germany
57

Who develops what

Add Dyslipidemias to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 31 programs from 19 companies, 26 with this as their studies’ main aim; 4 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Yuhan, AstraZeneca and Chong Kun Dang Pharmaceutical here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
inclisiranRecent, limited
Evidence
  • NCT07803822 · Lepu Medical · Phase 2 · live · background · “Inclisiran Sodium Injection” · registered Sep 2026
Novartis97% of its industry studiesUS: Novartis (FDA 2021)EU: Novartis (EMA 2020)11 study
AD-218ARecent, limited
Evidence
  • NCT05400317 · Yuhan Corporation · Phase 3 · live · comparator · “AD-218A” · registered May 2022
—11 study
DW5421ARecent, limited
Evidence
  • NCT07444762 · Daewon Pharmaceutical Co., Ltd. · Phase 3 · background · “DW5421A” · registered Feb 2026
—11 study

12 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
rosuvastatinApproved: US☆ Track1 live phase-3 study: NCT06834932AstraZeneca
laroprovstat☆ Track1 live phase-3 study: NCT06834932AstraZeneca
zodasiran☆ Track1 live phase-3 study: NCT07473843Arrowhead Pharmaceuticals
CMG190303☆ Track1 live phase-3 study: NCT06772168CMG Pharmaceutical Co. Ltd

The 4 in phase 3 with the nearest primary completion, of 31 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 22 Feb 2027 est.rosuvastatin, laroprovstat · AstraZeneca · Phase 3 main aimNCT06834932 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia — primary endpoint: AZD0780 Concentrations in plasma (PART A) · 432 enrolled
  • 26 Apr 2027 est.DII235 · Novartis · Phase 2 registry mapping onlyNCT07235046 A Study of DII235 in Adults With Elevated Lipoprotein(a) — primary endpoint: Time averaged percentage change from baseline between Day 60 and Day 180 · 234 enrolled
  • 31 May 2027 est.RBD5044 · Suzhou Ribo Life Science Co., Ltd. · Phase 2 main aimNCT06797401 Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia — primary endpoint: Change from baseline in triglyceride (TG) levels at week 16 · 120 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Dyslipidemias studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Statins 5 open · PCSK9 inhibitors 2 open · Angiotensin receptor blockers (ARBs) 20 · DPP-4 inhibitors 14 · Calcium channel blockers 13

Coming up

63studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger. 11 (10%) take children under 18. 4 (4%) are for women only and 0 (0%) for men only; 29 (26%) take healthy volunteers.

Recruiting studies that take each age, of 112
AgeWomenMen
1010 (9%)9 (8%)
1857 (51%)55 (49%)
3093 (83%)90 (80%)
4097 (87%)94 (84%)
50102 (91%)99 (88%)
6596 (86%)94 (84%)
7586 (77%)85 (76%)
8564 (57%)63 (56%)

Across all 1,249 studies, recruiting or not: 46% stop at 75 or younger and 27% at 65; 9% take children; 3% are for women only and 5% for men only; 32% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Dyslipidemias studies take

Of 83 phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 12 mo1–10 · 83 studies2 mo1–8 · 77 studies—
Phase 213 mo7–21 · 43 studies12 mo8–18 · 35 studies—
Phase 322 mo12–45 · 62 studies22 mo12–36 · 52 studies—
Phase 429 mo22–40 · 37 studies——
Interventional, no phase16 mo8–41 · 205 studies—18 mo7–42 · 194 studies
Observational40 mo23–118 · 90 studies31 mo19–40 · 34 studies81 mo30–203 · 56 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,249. Browse all 1,249 → or search them.